Senores Pharmaceuticals is currently trading at Rate RS 819.50, registering a gain of 3.95 points or 0.48% compared to its previous close of Rate RS 815.55 on the BSE.

The stock opened at Rate RS 844.00 and moved between a high of Rate RS 844.00 and a low of Rate RS 810.00 during the session. A total of 7,237 shares have been traded so far.

The BSE Group ‘B’ stock, with a face value of Rate RS 10, has recorded a 52-week high of Rate RS 847.90 on 15-Dec-2025 and a 52-week low of Rate RS 440.00 on 13-Jan-2025. Over the past week, the scrip’s high and low stood at Rate RS 847.90 and Rate RS 757.00, respectively. The company’s current market capitalization is Rate RS 3,763.73 crore.

Shareholding pattern shows promoters holding 45.80% stake in the company, while Institutions and Non-Institutions hold 12.89% and 41.31%, respectively.

In a significant development, Senores Pharmaceuticals has received approval to acquire 100% share capital of Apnar Pharma. The company has entered into a Share Purchase Agreement (SPA) with Apnar Pharma, which is engaged in the manufacturing of generic pharmaceutical formulations and operates a US FDA, UK-MHRA, and Health Canada approved manufacturing facility near Vadodara, Gujarat.

The acquisition will be completed in two tranches—the first tranche is expected to be completed by March 2026 within the current fiscal year, while the second tranche is anticipated to conclude by Q2 of FY 2027. Upon completion, Apnar Pharma will become a wholly owned subsidiary of Senores Pharmaceuticals. The proposal was reviewed and approved by the Management Committee of the Board of Directors in its meeting held on December 15, 2025.

Senores Pharmaceuticals is a global, research-driven pharmaceutical company focused on developing and manufacturing a broad portfolio of generic pharmaceutical products in the B2B segment, primarily catering to regulated markets across multiple therapeutic areas and dosage forms.